German firm Miltenyi Biotec acquires Swiss biosensor startup lino Biotech
lino Biotech, a biosensor company and the world's only provider of Focal Molography, has announced that it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.
Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.
Headquartered in Bergisch Gladbach, Miltenyi Biotech has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.
Under the terms of the transaction, Miltenyi Biotech will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds. The specific terms of the transaction were not disclosed.
Dr. Mirko Stange, CEO, lino Biotech: "lino´s innovative biosensor platform and Miltenyi's cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays.”
lino's headquarters in Zurich will be further expanded for research, chip, and application development.
